The selling point for these healthier patients is to get better 1-2 days faster and to lower risk of long Covid. But sales to low risk patients is always going to be more modest unless you have more virulent variants I think Ironically the drug interactions matter more for the higher risk patients (who not surprisingly take more drugs w potential interactions)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.